N4 - Neuroscience in the Clinic: Immunotherapies in Neurological Disease
| Event Time: | Wednesday May 8, 2019 1:00 pm to 3:00 pm |
| Topic(s): | Autoimmune Neurology, Neuromuscular and Clinical Neurophysiology (EMG) |
| Director(s): | John Corboy MD, FAAN, Holly Hinson MD, MCR, FAAN |
| Description: | Over the last 30 years, the use of immunotherapies for Neurological disease has greatly expanded and become more specific for distinct targets. This program will use neuromyelitis optica spectrum disorder (NMOSD) as a disease paradigm to investigate the role of immunotherapies in neurologic illness. NMOSD is characterized by recurrent attacks of optic neuritis and longitudinally extensive transverse myelitis, caused by antibodies to aquaporin-4. Attack prevention with immunosuppressive drugs is currently considered the standard of care, with interleukin-6 receptor inhibitor (SA-237), eculizumab and an anti-CD19 antibody (inebilizumab) emerging as potential therapies. This program will cover mechanism of action of the immunotherpies in question, risk management in special situations like pregnancy and vaccination, animal models, and the role of basic science as a route to novel therapies applied in the clinic. |
| Completion Message: | Participants should become familiar with the emerging role of immunotherpy in neurologic illness, including the practical application to NMOSD, and get an update on new break-throughs in the field with their basic science underpinnings. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge, Practice-Based Learning and Improvement |
| Start/End Time | Title | Faculty |
|---|---|---|
| 1:00 PM - 1:10 PM | Case Presentation | Stacey Clardy MD, PhD |
| 1:10 PM - 1:30 PM | Neuroscience Background | Jeffrey L. Bennett MD, PhD, FAAN |
| 1:30 PM - 1:40 PM | Clinical Follow up | Stacey Clardy MD, PhD |
| 1:40 PM - 2:00 PM | Summary of the Science and Future Directions | John Corboy MD, FAAN |
| 2:30 PM - 3:00 PM | Panel Discussion | Faculty |
| Speaker | Disclosure |
|---|---|
| Jeffrey L. Bennett, MD, PhD, FAAN | Dr. Bennett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Viela Bio, Genentech, Alexion, Roche, Chugai, Frequency Therapeutics, Clene Neuroscience, and Reistone. Dr. Bennett has received royalty, license fees, or contractual rights payments from Pure Biologics. Dr. Bennett has received research support from Mallinckrodt, and EMD Serono. |
| Stacey Clardy, MD, PhD | Dr. Clardy has received personal compensation in an editorial capacity for the Neurology Journal. |
| John Corboy, MD, FAAN | Dr. Corboy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Prime CME, Mylan, Novartis. Dr. Corboy has received personal compensation in an editorial capacity for Editor, Neurology: Clinical Practice. Dr. Corboy has received research support from Med Day, Novartis. |
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Pharmacokinetics, Pharmacodynamics, and Exposure-response Analyses of Ocrelizumab in Patients With Multiple Sclerosis |
Disclosure: Dr. Kletzl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche. Dr. Kletzl holds stock and/or stock options in Hoffmann-La Roche which sponsored research in which Dr. Kletzl was involved as an investigator. Dr. Kletzl holds stock and/or stock options in Hoffmann-La Roche. Dr. Kletzl has received research support from Hoffmann-La Roche.
|
| 1:00 PM | 002 | Subcutaneous Immunoglobulin in Myasthenia Gravis: Results of a North American Open Label Study |
Disclosure: Dr. Dimachkie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alnylam, Audentes, CSL-Behring, Sanofi Genzyme, Momenta, NuFactor, RMS Medical, Shire Takeda and Terumo. Dr. Dimachkie has received research support from Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, CSL-Behring, FDA/OPD, GlaxoSmithKline, Genentech, Grifols, MDA, NIH, Novartis, Genzyme, Octapharma, Orphazyme, UCB Biopharma, Viromed and TMA.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C7 -
Clinical Pearls in Autoimmune Neurology: Real World Cases
Stacey Clardy MD, PhD |
| 9:30 AM-11:30 AM |
|
C12 -
Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging, and Genetic Testing
Tahseen Mozaffar MD, FAAN |
| 1:30 PM-3:30 PM |
|
C25 -
Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology
Tahseen Mozaffar MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C46 -
Actualización en dolor de cabeza y trastornos neuromusculares (Update: Headache and Neuromuscular Disorder)
Jose Merino MD, MPhil, FAAN, Dario Beltran MD, FAAN |
|
C36 -
Mastering EMG Waveform Recognition Skills in Just Two Hours!
Devon Rubin MD, FAAN |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 1:00 PM-3:00 PM |
|
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Adam Quick MD, Ralph Jozefowicz MD, FAAN |
|
C47 -
Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies
Amanda Peltier MD, MS |
|
S5 -
Therapeutics in ALS and SMA
|
| 3:30 PM-5:30 PM |
|
C65 -
Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia
Amanda Peltier MD, MS |
|
S11 -
Autoimmune CNS Inflammatory Disorders: Clinical Advances
|
| 7:00 AM-9:00 AM |
|---|
|
C171 -
Child Neurology: Neuromuscular/Autoimmune Neurology
Anne Connolly MD, FAAN |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 1:00 PM-3:00 PM |
|
C175 -
Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia
Laura Tormoehlen MD, FAAN |
| 1:00 PM-5:30 PM |
|
C191 -
Skills Workshop: Neuromuscular Ultrasound
(Registration Required)
Craig Zaidman MD |
| 2:00 PM-2:30 PM |
|
TALK CANCELLED: A Career in Autoimmune Neurology
Pooja Raibagkar MD |
| 3:30 PM-5:30 PM |
|
C192 -
Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission
Laura Tormoehlen MD, FAAN |
|
C195 -
Therapy in Neurology II: Neurocritical Care and Neuromuscular Disease
Madhu Soni MD, FAAN |
|
S43 -
Immunotherapies and Drug Trials in Autoimmune Neurological Disorders
|
|
S42 -
Neuromuscular Disorders
|
| 7:00 AM-9:00 AM |
|---|
|
C243 -
Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis
Michael Weiss MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S58 -
Therapeutics in Neuromuscular Disorders
|
| 2:00 PM-2:45 PM |
|
Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1
Nicholas Johnson MD, FAAN |
|
Consensus-Based Care Recommendations for Adults with haha
|
| 3:30 PM-4:30 PM |
|
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |